Qingdao Municipal Hospital, Qingdao 266071, PR China.
Pharmacy Department, Cheeloo College of Medicine, Shandong University, Jinan 250000, PR China.
Biomark Med. 2019 Feb;13(2):95-104. doi: 10.2217/bmm-2018-0256. Epub 2019 Feb 15.
To assess SLC6A6 expression in gastric cancer, its correlation with patients' clinicopathological features and survival, and the possible epigenetic regulation mechanism.
Expression profiles and methylation data were obtained from the Gene Expression Omnibus database and the Cancer Genome Atlas. The SLC6A6's protein level were obtained from the Human Protein Atlas. Correlations between SLC6A6 expression and clinicopathological features were assessed using the χ test, and survival by the Kaplan-Meier analysis. By analyzing methylation data, the mechanisms of SLC6A6 dysregulation were investigated.
SLC6A6 expression was higher in gastric cancer, and indicated poor prognosis. Low-methylation levels were significantly related to high SLC6A6 expression.
SLC6A6 may be a potential prognostic marker and therapeutic target. Hypomethylation contributes to SLC6A6 upregulation in gastric cancer.
评估 SLC6A6 在胃癌中的表达，及其与患者临床病理特征和生存的相关性，并探讨可能的表观遗传调控机制。
从基因表达综合数据库和癌症基因组图谱中获取 SLC6A6 的表达谱和甲基化数据，从人类蛋白质图谱中获取 SLC6A6 的蛋白水平。采用卡方检验评估 SLC6A6 表达与临床病理特征的相关性，采用 Kaplan-Meier 分析评估生存情况。通过分析甲基化数据，研究 SLC6A6 失调的机制。
SLC6A6 在胃癌中表达升高，提示预后不良。低甲基化水平与 SLC6A6 高表达显著相关。
SLC6A6 可能是一个有潜力的预后标志物和治疗靶点。在胃癌中，低甲基化导致 SLC6A6 上调。
